Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B

Pimsiri Sripongpun; W Ray Kim; Ajitha Mannalithara; Allison Kwong; Tami Daugherty; Aparna Goel; Paul Y Kwo

doi:10.1016/j.cgh.2020.11.047

Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B

Clin Gastroenterol Hepatol. 2022 Jan;20(1):230-232. doi: 10.1016/j.cgh.2020.11.047. Epub 2020 Dec 4.

Authors

Pimsiri Sripongpun¹, W Ray Kim², Ajitha Mannalithara³, Allison Kwong³, Tami Daugherty³, Aparna Goel³, Paul Y Kwo³

Affiliations

¹ Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California; Gastroenterology and Hepatology Unit, Division of Internal Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
² Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California. Electronic address: wrkim@stanford.edu.
³ Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.

PMID: 33285291
DOI: 10.1016/j.cgh.2020.11.047

Abstract

Persistent serum alanine aminotransferase (ALT) elevation in nucleotide/nucleoside analogue (NA)-treated patients with chronic hepatitis B (CHB) has been associated with unfavorable long-term outcomes.¹ It has been consistently shown that a higher proportion of patients receiving tenofovir alafenamide (TAF) achieve normal ALT in comparison with recipients of tenofovir disoproxil fumarate,^2-5 the mechanism for which remains unknown.².

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alanine / therapeutic use
Alanine Transaminase
Antiviral Agents / therapeutic use
Diabetes Mellitus* / drug therapy
Hepatitis B, Chronic* / drug therapy
Humans
Tenofovir / analogs & derivatives

Substances

Antiviral Agents
Tenofovir
Alanine Transaminase
tenofovir alafenamide
Alanine